Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-CIN With Anti-PD-1 Therapy for Recurrent HPV16-associated Cancers
NCT05132803Phase 1Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TA-CIN in cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of patients who successfully receive at least one intratumoral vaccination at 10 weeks. Planned start Aug 2021; status: withdrawn.
02
Drugs
TA-CIN
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05132803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132803.